Prelude Therapeutics
PRLD
62 hedge funds and large institutions have $119M invested in Prelude Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 22 reducing their positions, and 17 closing their positions.
2.98% less ownership
Funds ownership: 71.61% → 68.63% (-3%)
9% less funds holding
Funds holding: 68 → 62 (-6)
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
27% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 22
50% less capital invested
Capital invested by funds: $235M → $119M (-$117M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$613K |
| 2 |
Two Sigma Advisers
New York
|
+$556K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$502K |
| 4 |
D.E. Shaw & Co
New York
|
+$470K |
| 5 |
CANY
Caxton Associates (New York)
New York
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.44M |
| 2 |
BlackRock
New York
|
-$2.66M |
| 3 |
State Street
Boston,
Massachusetts
|
-$845K |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$490K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$411K |
PRLD Hedge Fund Activity: Q2 2022 in Review
62 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Prelude Therapeutics (PRLD) for Q2 2022, worth a combined $119M — down 50% from $235M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of PRLD and 13 opened new positions — a net loss of 4 holders — while 22 trimmed existing stakes and 16 added.
The largest buyer was Renaissance Technologies, adding an estimated $613K. The largest seller was Fidelity Investments, cutting an estimated $5.44M.
- 62 institutional investors held Prelude Therapeutics (PRLD) as of Q2 2022, down from 68 in Q1 2022.
- Funds reported $119M of Prelude Therapeutics stock for Q2 2022, down 50% quarter-over-quarter.
- 13 funds opened new Prelude Therapeutics positions in Q2 2022 and 17 closed out, a net change of -4 holders.
- The largest Prelude Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $613K added.
- The largest Prelude Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $5.44M sold.
Based on aggregated 13F filings for Q2 2022.